CN106035806A - 一种茶粉组合物及其制备方法和应用 - Google Patents
一种茶粉组合物及其制备方法和应用 Download PDFInfo
- Publication number
- CN106035806A CN106035806A CN201610437434.7A CN201610437434A CN106035806A CN 106035806 A CN106035806 A CN 106035806A CN 201610437434 A CN201610437434 A CN 201610437434A CN 106035806 A CN106035806 A CN 106035806A
- Authority
- CN
- China
- Prior art keywords
- powder
- tea
- tea powder
- parts
- lactobacillus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000843 powder Substances 0.000 title claims abstract description 179
- 239000000203 mixture Substances 0.000 title claims abstract description 101
- 238000002360 preparation method Methods 0.000 title claims abstract description 11
- 210000004185 liver Anatomy 0.000 claims abstract description 44
- 239000006041 probiotic Substances 0.000 claims abstract description 43
- 235000018291 probiotics Nutrition 0.000 claims abstract description 43
- 239000002994 raw material Substances 0.000 claims abstract description 35
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims abstract description 18
- 238000002156 mixing Methods 0.000 claims abstract description 15
- 244000010000 Hovenia dulcis Species 0.000 claims abstract description 11
- 235000008584 Hovenia dulcis Nutrition 0.000 claims abstract description 11
- 240000008042 Zea mays Species 0.000 claims abstract description 10
- 235000002017 Zea mays subsp mays Nutrition 0.000 claims abstract description 10
- 102000015636 Oligopeptides Human genes 0.000 claims abstract description 9
- 108010038807 Oligopeptides Proteins 0.000 claims abstract description 9
- 229960003080 taurine Drugs 0.000 claims abstract description 9
- 235000013305 food Nutrition 0.000 claims abstract description 6
- 235000013616 tea Nutrition 0.000 claims description 114
- 241000894006 Bacteria Species 0.000 claims description 46
- 230000000529 probiotic effect Effects 0.000 claims description 39
- 235000006468 Thea sinensis Nutrition 0.000 claims description 20
- 235000020333 oolong tea Nutrition 0.000 claims description 20
- 239000002671 adjuvant Substances 0.000 claims description 13
- 208000007848 Alcoholism Diseases 0.000 claims description 11
- 201000007930 alcohol dependence Diseases 0.000 claims description 11
- 241000186000 Bifidobacterium Species 0.000 claims description 10
- 241000233805 Phoenix Species 0.000 claims description 10
- 235000013399 edible fruits Nutrition 0.000 claims description 10
- 235000016383 Zea mays subsp huehuetenangensis Nutrition 0.000 claims description 9
- 235000009973 maize Nutrition 0.000 claims description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 8
- 240000006053 Garcinia mangostana Species 0.000 claims description 6
- 235000017048 Garcinia mangostana Nutrition 0.000 claims description 6
- 244000068988 Glycine max Species 0.000 claims description 6
- 235000010469 Glycine max Nutrition 0.000 claims description 6
- 229920001202 Inulin Polymers 0.000 claims description 6
- 229920002472 Starch Polymers 0.000 claims description 6
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims description 6
- 229940029339 inulin Drugs 0.000 claims description 6
- 229920001542 oligosaccharide Polymers 0.000 claims description 6
- 150000002482 oligosaccharides Polymers 0.000 claims description 6
- 235000019698 starch Nutrition 0.000 claims description 6
- 239000008107 starch Substances 0.000 claims description 6
- 229920002101 Chitin Polymers 0.000 claims description 5
- 229920001661 Chitosan Polymers 0.000 claims description 5
- 240000001046 Lactobacillus acidophilus Species 0.000 claims description 5
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 claims description 5
- 241000218588 Lactobacillus rhamnosus Species 0.000 claims description 5
- 239000001913 cellulose Substances 0.000 claims description 5
- 229920002678 cellulose Polymers 0.000 claims description 5
- 235000010980 cellulose Nutrition 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- 229920001277 pectin Polymers 0.000 claims description 5
- 239000001814 pectin Substances 0.000 claims description 5
- 235000010987 pectin Nutrition 0.000 claims description 5
- 240000006024 Lactobacillus plantarum Species 0.000 claims description 4
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims description 4
- 241000191996 Pediococcus pentosaceus Species 0.000 claims description 4
- 244000202052 Poncirus trifoliata Species 0.000 claims description 4
- 235000000404 Poncirus trifoliata Nutrition 0.000 claims description 4
- 235000013325 dietary fiber Nutrition 0.000 claims description 4
- 210000000232 gallbladder Anatomy 0.000 claims description 4
- 239000003292 glue Substances 0.000 claims description 4
- 238000000227 grinding Methods 0.000 claims description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 4
- 229940072205 lactobacillus plantarum Drugs 0.000 claims description 4
- 229960000511 lactulose Drugs 0.000 claims description 4
- PFCRQPBOOFTZGQ-UHFFFAOYSA-N lactulose keto form Natural products OCC(=O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O PFCRQPBOOFTZGQ-UHFFFAOYSA-N 0.000 claims description 4
- 239000000377 silicon dioxide Substances 0.000 claims description 4
- 235000012239 silicon dioxide Nutrition 0.000 claims description 4
- PVXPPJIGRGXGCY-TZLCEDOOSA-N 6-O-alpha-D-glucopyranosyl-D-fructofuranose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)C(O)(CO)O1 PVXPPJIGRGXGCY-TZLCEDOOSA-N 0.000 claims description 3
- 241001608472 Bifidobacterium longum Species 0.000 claims description 3
- 244000241257 Cucumis melo Species 0.000 claims description 3
- 235000015510 Cucumis melo subsp melo Nutrition 0.000 claims description 3
- AYRXSINWFIIFAE-SCLMCMATSA-N Isomaltose Natural products OC[C@H]1O[C@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)[C@@H](O)[C@@H](O)[C@@H]1O AYRXSINWFIIFAE-SCLMCMATSA-N 0.000 claims description 3
- 241000186660 Lactobacillus Species 0.000 claims description 3
- 244000199866 Lactobacillus casei Species 0.000 claims description 3
- 235000013958 Lactobacillus casei Nutrition 0.000 claims description 3
- 241000186604 Lactobacillus reuteri Species 0.000 claims description 3
- 241000186869 Lactobacillus salivarius Species 0.000 claims description 3
- 241001465754 Metazoa Species 0.000 claims description 3
- FJJCIZWZNKZHII-UHFFFAOYSA-N [4,6-bis(cyanoamino)-1,3,5-triazin-2-yl]cyanamide Chemical compound N#CNC1=NC(NC#N)=NC(NC#N)=N1 FJJCIZWZNKZHII-UHFFFAOYSA-N 0.000 claims description 3
- 235000010443 alginic acid Nutrition 0.000 claims description 3
- 229920000615 alginic acid Polymers 0.000 claims description 3
- 229940009291 bifidobacterium longum Drugs 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 claims description 3
- 229940039696 lactobacillus Drugs 0.000 claims description 3
- 229940017800 lactobacillus casei Drugs 0.000 claims description 3
- 229940001882 lactobacillus reuteri Drugs 0.000 claims description 3
- JCQLYHFGKNRPGE-FCVZTGTOSA-N lactulose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 JCQLYHFGKNRPGE-FCVZTGTOSA-N 0.000 claims description 3
- 235000013336 milk Nutrition 0.000 claims description 3
- 239000008267 milk Substances 0.000 claims description 3
- 210000004080 milk Anatomy 0.000 claims description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims description 2
- 241000186018 Bifidobacterium adolescentis Species 0.000 claims description 2
- 241000186016 Bifidobacterium bifidum Species 0.000 claims description 2
- 241000186012 Bifidobacterium breve Species 0.000 claims description 2
- DCXXMTOCNZCJGO-UHFFFAOYSA-N Glycerol trioctadecanoate Natural products CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 claims description 2
- 241000218492 Lactobacillus crispatus Species 0.000 claims description 2
- 241001147746 Lactobacillus delbrueckii subsp. lactis Species 0.000 claims description 2
- 241000186840 Lactobacillus fermentum Species 0.000 claims description 2
- 241000186606 Lactobacillus gasseri Species 0.000 claims description 2
- 240000002605 Lactobacillus helveticus Species 0.000 claims description 2
- 235000013967 Lactobacillus helveticus Nutrition 0.000 claims description 2
- 241001468157 Lactobacillus johnsonii Species 0.000 claims description 2
- 241000191998 Pediococcus acidilactici Species 0.000 claims description 2
- UQZIYBXSHAGNOE-USOSMYMVSA-N Stachyose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO[C@@H]2[C@@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O2)O1 UQZIYBXSHAGNOE-USOSMYMVSA-N 0.000 claims description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 229940002008 bifidobacterium bifidum Drugs 0.000 claims description 2
- 235000012343 cottonseed oil Nutrition 0.000 claims description 2
- 239000004310 lactic acid Substances 0.000 claims description 2
- 235000014655 lactic acid Nutrition 0.000 claims description 2
- 229940054346 lactobacillus helveticus Drugs 0.000 claims description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 2
- UQZIYBXSHAGNOE-XNSRJBNMSA-N stachyose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)O2)O)O1 UQZIYBXSHAGNOE-XNSRJBNMSA-N 0.000 claims description 2
- 235000013311 vegetables Nutrition 0.000 claims description 2
- 239000000811 xylitol Substances 0.000 claims description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 2
- 229960002675 xylitol Drugs 0.000 claims description 2
- 235000010447 xylitol Nutrition 0.000 claims description 2
- 241001122767 Theaceae Species 0.000 claims 10
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 claims 2
- 241000193830 Bacillus <bacterium> Species 0.000 claims 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims 1
- 235000013351 cheese Nutrition 0.000 claims 1
- 239000000686 essence Substances 0.000 claims 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 1
- 239000008108 microcrystalline cellulose Substances 0.000 claims 1
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 1
- 229960001866 silicon dioxide Drugs 0.000 claims 1
- 244000269722 Thea sinensis Species 0.000 abstract description 91
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract description 54
- 230000000694 effects Effects 0.000 abstract description 45
- 235000016709 nutrition Nutrition 0.000 abstract description 6
- 238000009826 distribution Methods 0.000 abstract description 5
- 239000004615 ingredient Substances 0.000 abstract description 5
- 238000000034 method Methods 0.000 abstract description 4
- 239000000463 material Substances 0.000 abstract description 3
- 230000035764 nutrition Effects 0.000 abstract description 3
- 230000008901 benefit Effects 0.000 abstract description 2
- 235000018142 Hedysarum alpinum var americanum Nutrition 0.000 abstract 1
- 240000006461 Hedysarum alpinum var. americanum Species 0.000 abstract 1
- 235000017784 Mespilus germanica Nutrition 0.000 abstract 1
- 244000182216 Mimusops elengi Species 0.000 abstract 1
- 235000000560 Mimusops elengi Nutrition 0.000 abstract 1
- 240000006079 Schisandra chinensis Species 0.000 abstract 1
- 235000008422 Schisandra chinensis Nutrition 0.000 abstract 1
- 240000001949 Taraxacum officinale Species 0.000 abstract 1
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 abstract 1
- 235000007837 Vangueria infausta Nutrition 0.000 abstract 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 abstract 1
- 235000005822 corn Nutrition 0.000 abstract 1
- 230000002195 synergetic effect Effects 0.000 abstract 1
- 210000003813 thumb Anatomy 0.000 abstract 1
- 230000000968 intestinal effect Effects 0.000 description 22
- 150000004676 glycans Chemical class 0.000 description 16
- 229920001282 polysaccharide Polymers 0.000 description 16
- 239000005017 polysaccharide Substances 0.000 description 16
- 206010067482 No adverse event Diseases 0.000 description 14
- 235000013824 polyphenols Nutrition 0.000 description 11
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 10
- 230000001476 alcoholic effect Effects 0.000 description 10
- 231100000753 hepatic injury Toxicity 0.000 description 10
- 230000035622 drinking Effects 0.000 description 9
- 230000002708 enhancing effect Effects 0.000 description 9
- 230000006870 function Effects 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 9
- 230000037396 body weight Effects 0.000 description 8
- 229910052760 oxygen Inorganic materials 0.000 description 8
- 239000001301 oxygen Substances 0.000 description 8
- 150000008442 polyphenolic compounds Chemical class 0.000 description 8
- 238000011160 research Methods 0.000 description 8
- 102000003929 Transaminases Human genes 0.000 description 7
- 108090000340 Transaminases Proteins 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- 206010067125 Liver injury Diseases 0.000 description 6
- 230000003064 anti-oxidating effect Effects 0.000 description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 230000003647 oxidation Effects 0.000 description 6
- 238000007254 oxidation reaction Methods 0.000 description 6
- 150000003254 radicals Chemical class 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 235000013361 beverage Nutrition 0.000 description 5
- 238000003304 gavage Methods 0.000 description 5
- -1 polyphenol compound Chemical class 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 235000014101 wine Nutrition 0.000 description 5
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 4
- 241000628997 Flos Species 0.000 description 4
- 235000005487 catechin Nutrition 0.000 description 4
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 229950001002 cianidanol Drugs 0.000 description 4
- 208000019425 cirrhosis of liver Diseases 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000002443 hepatoprotective effect Effects 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 230000000813 microbial effect Effects 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 230000002000 scavenging effect Effects 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- 229960005486 vaccine Drugs 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 208000005584 Alcoholic Intoxication Diseases 0.000 description 3
- 108020002663 Aldehyde Dehydrogenase Proteins 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000002158 endotoxin Substances 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 239000000049 pigment Substances 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 231100000167 toxic agent Toxicity 0.000 description 3
- 239000003440 toxic substance Substances 0.000 description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 2
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 101710098398 Probable alanine aminotransferase, mitochondrial Proteins 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102100040247 Tumor necrosis factor Human genes 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 229930182830 galactose Natural products 0.000 description 2
- 210000003736 gastrointestinal content Anatomy 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 235000009569 green tea Nutrition 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000031891 intestinal absorption Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 230000004792 oxidative damage Effects 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- XWZAWHJNTHSHGD-SIDOVBMKSA-N (2S)-6-amino-N-[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]-2-[[(2S)-2-[[(2S)-2-amino-3-phenylpropanoyl]amino]propanoyl]amino]hexanamide Polymers CC(C)C[C@H](NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@@H](N)Cc1ccccc1)C(N)=O XWZAWHJNTHSHGD-SIDOVBMKSA-N 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 description 1
- 208000022309 Alcoholic Liver disease Diseases 0.000 description 1
- 206010070545 Bacterial translocation Diseases 0.000 description 1
- 208000001378 Carbon Tetrachloride Poisoning Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 244000205754 Colocasia esculenta Species 0.000 description 1
- 235000006481 Colocasia esculenta Nutrition 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 108010001202 Cytochrome P-450 CYP2E1 Proteins 0.000 description 1
- 102100024889 Cytochrome P450 2E1 Human genes 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 206010016275 Fear Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010061998 Hepatic lesion Diseases 0.000 description 1
- 101000588302 Homo sapiens Nuclear factor erythroid 2-related factor 2 Proteins 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 206010022678 Intestinal infections Diseases 0.000 description 1
- IPMYMEWFZKHGAX-UHFFFAOYSA-N Isotheaflavin Natural products OC1CC2=C(O)C=C(O)C=C2OC1C(C1=C2)=CC(O)=C(O)C1=C(O)C(=O)C=C2C1C(O)CC2=C(O)C=C(O)C=C2O1 IPMYMEWFZKHGAX-UHFFFAOYSA-N 0.000 description 1
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 1
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 1
- 241000186605 Lactobacillus paracasei Species 0.000 description 1
- 201000010538 Lactose Intolerance Diseases 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102100031701 Nuclear factor erythroid 2-related factor 2 Human genes 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- UXRMWRBWCAGDQB-UHFFFAOYSA-N Theaflavin Natural products C1=CC(C2C(CC3=C(O)C=C(O)C=C3O2)O)=C(O)C(=O)C2=C1C(C1OC3=CC(O)=CC(O)=C3CC1O)=CC(O)=C2O UXRMWRBWCAGDQB-UHFFFAOYSA-N 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- IKHGUXGNUITLKF-XPULMUKRSA-N acetaldehyde Chemical group [14CH]([14CH3])=O IKHGUXGNUITLKF-XPULMUKRSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 230000002075 anti-alcohol Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000006472 autoimmune response Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000007375 bacterial translocation Effects 0.000 description 1
- 235000013405 beer Nutrition 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000020299 breve Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000019225 fermented tea Nutrition 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 description 1
- 229940114124 ferulic acid Drugs 0.000 description 1
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 description 1
- 235000001785 ferulic acid Nutrition 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- HVQAJTFOCKOKIN-UHFFFAOYSA-N flavonol Natural products O1C2=CC=CC=C2C(=O)C(O)=C1C1=CC=CC=C1 HVQAJTFOCKOKIN-UHFFFAOYSA-N 0.000 description 1
- 150000002216 flavonol derivatives Chemical class 0.000 description 1
- 235000011957 flavonols Nutrition 0.000 description 1
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 1
- 235000003969 glutathione Nutrition 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 210000000224 granular leucocyte Anatomy 0.000 description 1
- 244000005709 gut microbiome Species 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000005965 immune activity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003870 intestinal permeability Effects 0.000 description 1
- 210000001865 kupffer cell Anatomy 0.000 description 1
- 125000002099 lactulose group Chemical group 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 230000004898 mitochondrial function Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 239000002417 nutraceutical Substances 0.000 description 1
- 235000021436 nutraceutical agent Nutrition 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 235000013406 prebiotics Nutrition 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 235000020095 red wine Nutrition 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000003307 slaughter Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 235000014620 theaflavin Nutrition 0.000 description 1
- IPMYMEWFZKHGAX-ZKSIBHASSA-N theaflavin Chemical compound C1=C2C([C@H]3OC4=CC(O)=CC(O)=C4C[C@H]3O)=CC(O)=C(O)C2=C(O)C(=O)C=C1[C@@H]1[C@H](O)CC2=C(O)C=C(O)C=C2O1 IPMYMEWFZKHGAX-ZKSIBHASSA-N 0.000 description 1
- 229940026509 theaflavin Drugs 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23F—COFFEE; TEA; THEIR SUBSTITUTES; MANUFACTURE, PREPARATION, OR INFUSION THEREOF
- A23F3/00—Tea; Tea substitutes; Preparations thereof
- A23F3/06—Treating tea before extraction; Preparations produced thereby
- A23F3/14—Tea preparations, e.g. using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/113—Acidophilus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/123—Bulgaricus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/125—Casei
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/137—Delbrueckii
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/143—Fermentum
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/145—Gasseri
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/147—Helveticus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/151—Johnsonii
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/169—Plantarum
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/173—Reuteri
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/175—Rhamnosus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/181—Salivarius
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/41—Pediococcus
- A23V2400/413—Acidilactici
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/41—Pediococcus
- A23V2400/427—Pentosaceus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/513—Adolescentes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/515—Animalis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/517—Bifidum
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/519—Breve
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/529—Infantis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/533—Longum
Abstract
本发明涉及营养食品领域,特别涉及一种茶粉组合物及其制备方法和应用。一种茶粉组合物,主要由以下原料混合而成,按重量份计,茶粉1~50份,益生菌0.1~20份,功能糖1~30份以及第二成分30~50份;第二成分包括蒲公英粉、五味子粉、甘草粉、罗汉果粉、红枣粉、枸杞粉、葛根粉、枳椇子粉、玉米低聚肽和牛磺酸中的至少两种以上。本发明还提供了茶粉组合物将各原料混匀即可,方法简单易行,各原料分布均一,且尽量保留了各原料之间的营养成分。本发明提供的茶粉组合物,将茶粉、益生菌、功能性糖和特定的辅料配合使用,各功能成分能够起到协同增强的作用,具有显著的解酒护肝的功效。
Description
技术领域
本发明涉及营养食品领域,具体而言,涉及一种茶粉组合物及其制备方法和应用。
背景技术
我国的酒文化源远流长,热情好客的中国人的饭桌上也不乏"劝酒"行为。酒精性肝损伤是指人体因摄入酒精而引起的肝脏损伤疾病,是饮酒引起的比较常见的肝脏病变。由于肝脏容易受到一些毒性物质损伤,长期酒精摄入引起肝脏中氧化力,由于氧化和抗氧化体系失衡,且肝脏对酒精毒性敏感进而引起酒精肝病。
酒精肝的发病率是与生活水平的提高紧密相关的,近几年随着我国经济发展水平的突飞猛进,人们的生活水平也发生了日新月异的变化,在日常饮食中白酒、啤酒、红酒等酒精类饮料的消费也大幅度增加。调査发现,酒精肝逐渐成为肝硬化的主要诱因,肝硬化病人中约有60%有长期过量饮酒的经历。另一方面,酒精肝的发病人群以中青年为主,80%的酒精肝患者在40岁左右。据估计,全世界醜酒人群多达1500万-2000万人,其中10%-20%(150万-400万)引发了程度不同的酒精性肝病。于此相对应的,长期过量饮酒导致的脂肪肝、肝硬化等巧脏疾病的发病人群在日趋扩大,严重肝硬化导致的死亡率也在不断攀升,引起了国内外医学界的广泛关注。
有鉴于此,特提出本发明。
发明内容
本发明的第一目的在于提供一种茶粉组合物,所述的茶粉组合物将茶粉、益生菌、功能性糖以及特定的辅料配合使用,各功能成分能够起到协同增强的作用,具有非常好的解酒护肝效果。
本发明的第二目的在于提供一种所述的茶粉组合物的制备方法,该方法制备简单,将各成分很好的混匀在一起,且不破坏各原料之间的营养成分。
本发明的第三目的在于提供所述的茶粉组合物在解酒护肝食品中的应用。
为了实现本发明的上述目的,特采用以下技术方案:
一种茶粉组合物,主要由以下原料混合而成,按重量份计,茶粉1~50份,益生菌0.1~20份,功能糖1~30份以及第二成分30~50份;
所述第二成分包括蒲公英粉、五味子粉、甘草粉、罗汉果粉、红枣粉、枸杞粉、葛根粉、枳椇子粉、玉米低聚肽和牛磺酸中的至少两种以上。
本发明中的茶粉特别是凤凰有机单丛茶(乌龙茶)经提取或研磨制得的茶粉中含有大量的茶多酚、茶多糖、茶色素等功能成分。茶多酚(TeaPolyphenol,TP)是茶粉中的有效成分,它是含有多酚类化合物的混合物,包含有儿茶素类、黄酮及黄酮醇类、花色素类和缩酚醛类等主要几种物质。对于茶多酚这一多酚类化合物,我国和世界各国己有了广泛的研究。通过这些研究,己发现了茶多酚大量的药理作用和保健作用,如抗菌、防癌抗癌、降血脂和保护心脑血管,护肝、抗氧化等作用,尤其是对于它抗氧化功能的研究己较为深入。正常人体和病理情况下,机体内会产生有害的白由基(freeardical),它性质活泼具有极强的氧化功能,产生过氧化脂质(lipidporxiden,LPO),LPO在体内不断的堆积,就会削弱和破坏生物膜的止常功能,影响活性物质的正常代谢。因此,清除体内有害白由基,对保持内环境的稳定和保证人们的身体健康有着及其重要的意义。实验发现,在刺激人多形核白细胞体系中,茶多酚对活性氧白由基(OFR)有很强烈的清除作用,其清除作用是VE的十八倍,VC的3-10倍。Osawa等研究表明,在对绿茶和黑茶提取出的儿茶素和茶黄素具有强烈的抑制脂质氧化和DNA因氧化而被破坏的功能。美国Katiyar等在对绿茶的研究中,为儿茶素(CE)及其衍生物(ECD)S的抗氧化强度提供了直接证据。此外,还发现其能够调动和激活体内的内源性抗氧化系统,提高SOD等酶类的活性,促使血浆中的LPO含量减少。
茶多糖具有广泛的生理活性,结构多样化。乌龙茶多糖是乌龙茶中生物活性最强的成分之一,种类多,已分离到就有100多种,包括水溶性、碱性、酸性多糖。且据研究表明,乌龙茶的多糖含量是所有茶种类中提取率最高的活性成分。一般的研究认为,茶多糖是主要的药效成分之一,具有极高的研究价值。乌龙茶多糖对羟自由基和超氧阴离子自由基均有清除作用,这在一定程度上表明了乌龙茶多糖的抗氧化能力。在乌龙茶多糖对ECV304细胞氧化损伤的保护作用的研究中发现,乌龙茶多糖具有保护细胞和抗氧化作用,其原因是乌龙茶多糖可以保护细胞,降低氧自由基对细胞器的损伤程度,也可以很好地抑制细胞调亡和细胞坏死,从而提高了细胞的存活率。乌龙茶多糖的护肝作用与抗氧化功能密切相关。根据Sugiyamaa等人的研究,乌龙茶中的多糖能减轻小鼠四氯化碳中毒所致的肝损害。以血清转氨酶、脂质过氧化物为指标发现,活性物质多糖浸膏对大鼠四氯化碳引起的巧损伤有明显保肝作用。
酒精经过胃进入小肠,由小肠吸收近80%,但小肠吸收速度较慢。肠道内长期高浓度酒精的存在,不仅可能导致肠道正常菌群失调,引起肠道益生菌数量减少,革兰氏阴性菌等致病菌过度生长,进而导致肠道内容物中内毒素增加;而且肠道中过量酒精和肠道菌群失衡还可能导致肠道通透性升高,进而引起肠道内容物中内毒素进入血液,导致血液中内毒素升高,引起肝脏损伤。另外,酒精在体内吸收后,主要在肝脏中代谢,代谢产物主要是乙醛和乙酸。其中最容易导致肝损伤的是乙醛,作为主要的毒性物质,它能够阻止线粒体的氧化从而使这一毒性物质不断地增加。当长期或者大量饮酒造成酒精浓度过高时线粒体功能发生紊乱,高活性的乙醛便在肝脏内积累,从而干扰肝细胞各个方面的功能。乙醛可以与肝脏内多种蛋白质结合形成乙醛蛋白的加合物,改变蛋白表面电荷构象,导致功能性蛋白质变性,甚至暴露一些表面抗原,从而刺激机体产生抗体引起自身免疫反应,导致肝脏损伤。
该茶粉混合物中含有益生菌,能定殖在肠道内,并通过促进有益菌的繁殖和抑制有害菌的生长来调节肠道菌群的平衡。另外,该混合物中含有功能糖,能作为益生菌的食物来源,促进益生菌的增殖。
肠道是人体最大的免疫器官,益生菌进入肠道内,可以诱发肠道免疫,并刺激胸腺,脾脏等免疫器官,促进巨噬细胞活性,通过增强B、T淋巴细胞对抗原刺激的反应性,发挥特异性免疫活性,从而增强机体的免疫功能。
在特定的辅料中,葛花枳椇子是最具有代表性的解酒药对,葛花功用为解酒醒脾,枳惧子具有清热利尿,解酒毒的功效,葛花与枳惧子相配,上下分消,使邪有去路,酒毒之邪既能从表而发散,又能从小便而解,两药作用相得益彰,大大增强解酒的功效。另外,现代实验进一步证明,葛花枳惧子配伍对慢性酒精性肝损伤大鼠“内毒素-Kupffer细胞-TNFα-肝脏炎症-肝细胞凋亡”途径有一定的影响特定的辅料中,内毒素及其激活肝Kupffer细胞产生炎症因子是酒精性肝损伤的重要机制。蒲公英能显著降低乙醇引起急性肝损伤小鼠血清ALT和AST水平,明显降低肝组织的MDA、NO和TNF-α水平诱发细胞凋亡的重要因素,蒲公英粉能通过抑制脂质过氧化反应对肝脏产生保护作用,减轻乙醇对肝脏的损伤;玉米低聚肽具有促进乙醇代谢的能力,它能及时清除乙醇代谢过程中所产生的大量自由基,改善酒醉作用,能加快ADH和ALDH合成速度并提高了线粒体中ADH和ALDH的酶活力从而起到醒酒的作用;牛磺酸对酒精性肝损伤具有良好的防治作用,在饮酒前、后服用牛磺酸均能延长机体对酒精的耐受时间、缩短醉酒维持时间,并可显著降低血液中乙醇浓度,提高肝脏中ADH和ALDH的活性,加强乙醇和乙醛在肝脏内的代谢,减少乙醇和乙醛对机体的毒性用。五味子粉、甘草粉、罗汉果粉、红枣粉和枸杞粉辅助配合,尽量减少酒对人体的不适。
本发明提供的茶粉组合物,将茶粉、益生菌、功能性糖和特定的辅料配合使用,各功能成分能够起到协同增强的作用,具有显著的解酒护肝的功效。
经品尝,本发明提供的茶粉组合物具有乌龙茶明显的香气,口感比较甘甜,滋味浓醇,润喉回甘强。
为了达到更好的协同增强效果,优选地,按重量份计,茶粉5~40份,益生菌5~15份,功能糖5~20份以及第二成分35~45份。
更优选地,按重量份计,茶粉20~30份,益生菌8~12份,功能糖10~15份以及第二成分40~45份。
乌龙茶特别是凤凰有机单丛茶经提取或研磨制得的茶粉中含有大量的茶多酚、茶多糖、茶色素等分子结构中具有活泼羟基氧的抗氧化物质,能捕获过量的自由基,终止自由基的连锁反应。体外抗氧化研究表明,茶叶中茶多酚含量与其自由基的清除能力呈现良好的量效关系。茶粉能提高机体抗氧化能力,主要表现在增加血浆VC水平,提高全血谷胱甘肽过氧化酶的活力和肝中超氧化物歧化酶的活力,从而有助于清除体内过量自由基;另外,其有助于降低肝、血清中脂质过氧化物的含量,延缓心肌脂褐素的形成,从而延缓人体衰老。此外,茶色素无论是从茶叶中直接提取,还是有茶多酚转化而来,都具有清除自由基的能力。茶粉中茶褐素对羟自由基、超氧阴离子自由基、DPPH自由基均具有一定的清除效果。
优选地,所述茶粉为乌龙茶经提取或研磨制得的茶粉。
更优选地,所述乌龙茶为凤凰有机单丛茶。
本发明的主要原料茶粉,既作为益生元的作用加强益生菌在肠道内的生长和作用,同时也是饮料功能和滋味的重要来源。
优选地,所述第二成分至少含有蒲公英粉、五味子粉、甘草粉、罗汉果粉、红枣粉、枸杞粉、葛根粉、枳椇子粉、玉米低聚肽、牛磺酸中的四种以上。任意四种以上的成与其他成分配合,达到很好的解酒护肝的功效。
益生菌是指当摄入一定数量后,能够对宿主的健康发挥有益作用的微生物活体,可直接作为添加剂服用,维持肠道菌群的平衡。益生菌的生理功能是通过直接或者间接的调整宿主肠道微生物的组成,激活宿主内源性微生物群或者免疫系统的活性来实现的。目前研究证实口服益生菌有助于缓解乳糖不耐症,预防或者治愈胃肠炎、抗生素相关性腹泻、旅行性腹泻、便秘及肠道感染,同时可抑制有害微生物在宿主肠道中定殖,对肠易激综合征、炎症性肠炎及结肠癌等肠道相关性疾病具有良好的预防和治疗作用。益生菌还可以有效地改善肠道菌群结构,纠正腹腔感染的动物肠道菌群紊乱,减少细菌易位,从而保护肠黏膜,还具有抑制病原菌,消除致癌因子,提高机体免疫力,降低胆固醇等功能。国内外许多学者开始关注益生菌与酒精性肝损伤是否具有关联性、能否对酒精引起的肝病起到一定的预防与治疗的作用。科学家饲喂鼠李糖乳杆菌LGG后,酒精性肝损伤小鼠肝脏TNF-α和p-P38(MAPK)蛋白水平、TLR4mRNA水平及ROS、CYP2E1蛋白及mRNA水平表达较模型组显著降低,而Nrf-2蛋白表达明显增加。表明鼠李糖乳杆菌可通过降低炎症反应和抗氧化途径缓解酒精对小鼠肝脏氧化损伤,达到修复酒精性肝损伤的作用。
进一步地,所述益生菌为双歧杆菌属和乳酸菌属的菌种中的任一种或多种;
所述双歧杆菌属包括以下种类的菌种:青春双歧杆菌、动物双歧杆菌、两歧双歧杆菌、短双歧杆菌、婴儿双歧杆菌、长双歧杆菌;
所述乳酸菌属包括以下种类的菌种:嗜酸乳杆菌、干酪乳杆菌、卷曲乳杆菌、保加利亚乳杆菌、德氏乳杆菌乳亚种、发酵乳杆菌、格氏乳杆菌、瑞士乳杆菌、约氏乳杆菌、副干酪乳杆菌、植物乳杆菌、罗伊氏乳杆菌、鼠李糖乳杆菌、唾液乳杆菌、戊糖片球菌、乳酸片球菌。
经验证,以上种类的益生菌与其他成分配合使用,均能起到很好的协同增强效果。
功能糖指对人体健康具有一定改善效果的功能性糖类,多是由2~10个单糖通过糖苷键连接形成直链或支链的低度聚合糖。功能糖的主要功能有:为益生菌提供营养,改善肠道菌群的种类,同时具有润肠通便的作用。
进一步地,所述功能糖包括功能性低聚糖和功能性膳食纤维;
所述功能性低聚糖包括水苏糖、棉籽糖、异麦芽酮糖、乳酮糖、低聚果糖、低聚木糖、低聚半乳糖、低聚异麦芽糖、低聚异麦芽酮糖、低聚龙胆糖、大豆低聚糖、低聚壳聚糖中的一种或几种;
所述功能性膳食纤维包括菊粉、天然抗性淀粉、果胶、藻胶、纤维素、魔芋多糖、瓜儿胶、甲壳素中的一种或几种。
优选地,所述原料还包括辅料,所述辅料为奶粉、二氧化硅、食用香精、木糖醇、微晶纤维素、二氧化硅、植物硬脂酸中的任意一种或多种。
辅料起到改善口感、易于制作成品的作用。
为了便于食用,进一步地,所述茶粉组合物为固态或液态,所述固态包括粉剂、颗粒剂。
液体可以为将茶粉组合物制成现用现制的饮料或者是可保藏的市售饮料的形式等等。
本发明还提供了上述茶粉组合物的制备方法,将各原料混匀即可。
混匀一般用混料机进行,一般混合的时间为10-15min即可得到各原料混匀的茶粉组合物。
本发明提供的茶粉组合物的制备方法,方法简单易行,各原料分布均一,且尽量保留了各原料之间的营养成分。
本发明还提供了上述的茶粉组合物在解酒护肝食品中的应用。
与现有技术相比,本发明的有益效果为:
(1)本发明提供的茶粉组合物将茶粉、益生菌、功能性糖和特定的辅料配合使用,各功能成分能够起到协同增强的作用,具有非常好的解酒护肝效果。
(2)本发明还特定限定了各成分的比例,以达到更好的协同增强效果。
(3)本发明还特定限定了辅料的种类,使各有效成分之间协同增强,达到更好的解酒护肝的功效。
(4)本发明还限定了茶粉、益生菌和功能性糖的种类,各成分之间相互配合,不仅具有很好的解酒护肝的功效,还具有维持肠道微生态健康和增强免疫力的功效,并且具有很好的味道和口感。
(5)本发明提供的茶粉组合物的制备方法,方法简单易行,各原料分布均一,且尽量保留了各原料之间的营养成分。
具体实施方式
下面将结合实施例对本发明的实施方案进行详细描述,但是本领域技术人员将会理解,下列实施例仅用于说明本发明,而不应视为限制本发明的范围。实施例中未注明具体条件者,按照常规条件或制造商建议的条件进行。所用试剂或仪器未注明生产厂商者,均为可以通过市售购买获得的常规产品。
实施例1
取以下各原料,按重量份计,茶粉1份,益生菌0.1份,功能糖1份以及第二成分30份;
茶粉为乌龙茶经提取制得的茶粉;
益生菌为CFU为109的乳酸片球菌、戊糖片球菌和植物乳杆菌以相同重量配比的混合菌;
功能糖为低聚半乳糖;
第二成分为葛根粉、枳椇子粉、蒲公英粉、五味子粉的混合物;
将各原料混匀,得到茶粉组合物。
实施例2
取以下各原料,按重量份计,茶粉5份,益生菌5份,功能糖5份以及辅料35份;
茶粉为乌龙茶研磨制得的茶粉;
益生菌为CFU为109的短双歧杆菌、长双歧杆菌、植物乳杆菌、干酪乳杆菌和鼠李糖乳杆菌的混合菌;
功能糖为异麦芽酮糖、乳酮糖、大豆低聚糖、菊粉、天然抗性淀粉、魔芋多糖的混合物;
第二成分为甘草粉、蒲公英粉、葛根粉、枳椇子粉的混合物;
将各原料放入混料机,混合10min,得到各原料混匀的茶粉组合物。
实施例3
取以下各原料,按重量份计,凤凰有机单丛茶经研磨制得的茶粉20份,CFU为109的鼠李糖乳杆菌2份,CFU为109的发酵乳杆菌3份,CFU为109的双歧杆菌3份,低聚果糖5份,魔芋多糖5份、甘草粉5份、枳椇子10份、牛磺酸5份、葛根粉10份、玉米低聚肽10份;
将各原料放入混料机,混合15min,得到各原料混匀的茶粉组合物。
实施例4
取以下各原料,按重量份计,茶粉30份,益生菌12份,功能糖15份以及第二成分45份;
茶粉为凤凰有机单丛茶经研磨制得的茶粉;
益生菌为两歧双歧杆菌、嗜酸乳杆菌、罗伊氏乳杆菌的混合菌;
功能糖为低聚龙胆糖、大豆低聚糖、低聚壳聚糖、菊粉、天然抗性淀粉、果胶、魔芋多糖、甲壳素的混合物;
第二成分为枸杞粉、葛根粉、五味子、枳椇子粉和玉米低聚肽的混合物;
将各原料放入混料机,混合10min,得到各原料混匀的茶粉组合物。
实施例5
取以下各原料,按重量份计,茶粉40份,益生菌15份,功能糖20份以及第二成分45份;
茶粉为凤凰有机单丛茶经研磨制得的茶粉;
益生菌为婴儿双歧杆菌、嗜酸乳杆菌、唾液乳杆菌、戊糖片球菌的混合菌;
功能糖为乳酮糖、低聚龙胆糖、大豆低聚糖、低聚壳聚糖、天然抗性淀粉、果胶、魔芋多糖、甲壳素的混合物;
第二成分为甘草粉、蒲公英粉、五味子粉、枸杞粉和玉米低聚肽的混合物;
将各原料放入混料机,混合10min,得到各原料混匀的茶粉组合物。
实施例6
取以下各原料,按重量份计,茶粉50份,益生菌20份,功能糖30份以及第二成分50份;
茶粉为凤凰有机单丛茶经研磨制得的茶粉;
益生菌为CFU为109的保加利亚乳杆菌;
功能糖为低聚异麦芽糖、菊粉和大豆低聚糖的混合物;
第二成分为蒲公英粉、五味子粉、葛根粉、枳椇子、牛磺酸的混合物;
将各原料放入混料机,混合15分钟,得到各原料混匀的茶粉组合物。
实施例7
取以下各原料,按重量份计,茶粉25份,益生菌10份,功能糖15份以及第二成分40份;
茶粉为凤凰有机单丛茶经提取或研磨制得的茶粉;
益生菌为CFU为109的动物双歧杆菌、嗜酸乳杆菌的混合菌;
功能糖为低聚壳聚糖、藻胶、纤维素、魔芋多糖的混合物;
第二成分为甘草粉、罗汉果粉、枳椇子粉、五味子粉、玉米低聚肽的混合物;
将各原料放入混料机,混合10min,得到各原料混匀的茶粉组合物。
实施例1-7制得的茶粉组合物可添加不同的辅料如菊粉、天然抗性淀粉、果胶、藻胶、纤维素、魔芋多糖、瓜儿胶、甲壳素中的一种或几种,根据需求制成不同的固态或液态,制成的固态可以为粉剂,也可以为颗粒剂等等;液态可以为将茶粉组合物制成现用现制的饮料或者是可保藏的市售饮料的形式等等。
试验例1
将实施例7制得的茶粉组合物通过给灌服白酒的大白鼠灌胃服用,测定其体重、肝脏重量、肝指数和血清转氨酶的变化情况,为茶粉组合物的解酒护肝作用提供科学的实验依据。具体实验如下:
取体重约300g的SD大鼠,随机分组为正常对照组、模型组和茶粉组合物组。正常对照组自由摄食、饮水,模型组和茶粉组合物组在正常喂养的基础上,按体重每日予10g/kg白酒进行造模,分两次灌胃,连续6周。茶粉混合物组于每次灌酒1h后灌胃茶粉混合物,7周后称量体重,并宰杀称量肝脏重量和测量。
1.测定指标
1.1体重和肝重测定
实验结束后称量大鼠体重,解剖取出肝脏并称量,计算肝脏指数。
1.2血清转氨酶测定
对血清中的谷草转氨酶(AST)和谷丙转氨酶(ALT)的含量进行测定。
2.结果
2.1体重、肝脏重量和肝脏指数
具体结果见表1。
表1大鼠体重、肝脏重量和肝脏指数
由表1可知,经7周饲养后,模型组的体重增加情况明显低于正常对照组,肝脏重量的增加情况和肝脏指数明显高于对照组。茶粉组合物组大鼠虽然同样灌服白酒,但由于其同时以茶粉组合物灌胃,使其肝脏重量增加情况和肝脏指数明显小于模型组,与正常对照组接近。说明茶粉组合物能显著减少由于饮酒造成的肝脏异常。
2.2血清转氨酶测定
血清转氨酶测定结果如表2所示。
表2大鼠血清转氨酶变化情况
组别 | AST(U/L) | ALT(U/L) |
正常对照组 | 157.71 | 70.56 |
模型组 | 195.10 | 105.85 |
茶粉组合物组 | 166.48 | 89.07 |
由表2可以看出,模型组的谷草转氨酶(AST)和谷丙转氨酶(ALT)明显高于正常对照组,茶粉组合物组的AST和ALT介于对照组和模型组之间,表明茶粉组合物能降低大鼠血清中的转氨酶,对醉酒大鼠具有一定的解酒和护肝的作用。
另外,其他实施例提供的茶粉组合物的效果与实施例7效果基本一致。
试验例2
将实施例1-7制得的茶粉组合物在醉酒前后分别饮用进行效果评价,同时以凤凰有机单丛茶粉作为对照组,每组分别选用50个人饮用。每次饮用时,将1.5g产品溶于300ml左右的温水中。饮用后根据喝酒时以及醒酒后的反应就行评价,结果如表3所示。
表3饮用结果
实施例 | 喝酒时反应 | 醒酒后反应 |
实施例1 | 无不良反应 | 无不良反应 |
实施例2 | 无不良反应 | 无不良反应 |
实施例3 | 无不良反应 | 无不良反应 |
实施例4 | 无不良反应 | 无不良反应 |
实施例5 | 无不良反应 | 无不良反应 |
实施例6 | 无不良反应 | 无不良反应 |
实施例7 | 无不良反应 | 无不良反应 |
对照组 | 出现不适 | 出现头痛、恶心等不良症状 |
从表3可以看出,本发明提供的茶粉组合物具有非常好的解酒效果,并且经常饮用,酒量还有一定的提升。
另外,经品尝,本发明提供的茶粉组合物具有乌龙茶明显的香气,口感比较甘甜,滋味浓醇,润喉回甘强。
本发明提供的茶粉组合物适合各个年龄段的人群饮用,无任何毒副作用,一天可饮用一次或多次,根据自身条件可随意选择,每次1.5g溶于300ml左右的温水中。
本发明提供的茶粉组合物中含有益生菌,通过促进有益菌的繁殖和抑制有害菌的生长来调节肠道菌群的平衡;另外,该混合物中含有功能糖,能作为益生菌的食物来源,促进益生菌的增殖;肠道是人体最大的免疫器官,益生菌进入肠道内,可以诱发肠道免疫,并刺激胸腺,脾脏等免疫器官,促进巨噬细胞活性,通过增强B、T淋巴细胞对抗原刺激的反应性,发挥特异性免疫活性,从而增强机体的免疫功能。各功能成分能够起到协同增强的作用,在调节肠道微生态的同时,还能够起到很好的增强免疫力的效果。益生菌在人体内通过产生如阿魏酸、SOD等降低氧化产物含量,提高机体的抗氧化能力。
尽管已用具体实施例来说明和描述了本发明,然而应意识到,在不背离本发明的精神和范围的情况下可以作出许多其它的更改和修改。因此,这意味着在所附权利要求中包括属于本发明范围内的所有这些变化和修改。
Claims (10)
1.一种茶粉组合物,其特征在于,主要由以下原料混合而成,按重量份计,茶粉1~50份,益生菌0.1~20份,功能糖1~30份以及第二成分30~50份;
所述第二成分包括蒲公英粉、五味子粉、甘草粉、罗汉果粉、红枣粉、枸杞粉、葛根粉、枳椇子粉、玉米低聚肽和牛磺酸中的至少两种以上。
2.根据权利要求1所述的茶粉组合物,其特征在于,按重量份计,茶粉5~40份,益生菌5~15份,功能糖5~20份以及第二成分35~45份;
优选地,按重量份计,茶粉20~30份,益生菌8~12份,功能糖10~15份以及第二成分40~45份。
3.根据权利要求1所述的茶粉组合物,其特征在于,所述茶粉为乌龙茶经提取或研磨制得的茶粉;所述乌龙茶优选为凤凰有机单丛茶。
4.根据权利要求1所述的茶粉组合物,其特征在于,所述第二成分至少含有蒲公英粉、五味子粉、甘草粉、罗汉果粉、红枣粉、枸杞粉、葛根粉、枳椇子粉、玉米低聚肽和牛磺酸中的四种以上。
5.根据权利要求1所述的茶粉组合物,其特征在于,所述益生菌为双歧杆菌属和乳酸菌属的菌种中的任一种或多种;
所述双歧杆菌属包括以下种类的菌种:青春双歧杆菌、动物双歧杆菌、两歧双歧杆菌、短双歧杆菌、婴儿双歧杆菌、长双歧杆菌;
所述乳酸菌属包括以下种类的菌种:嗜酸乳杆菌、干酪乳杆菌、卷曲乳杆菌、保加利亚乳杆菌、德氏乳杆菌乳亚种、发酵乳杆菌、格氏乳杆菌、瑞士乳杆菌、约氏乳杆菌、副干酪乳杆菌、植物乳杆菌、罗伊氏乳杆菌、鼠李糖乳杆菌、唾液乳杆菌、戊糖片球菌、乳酸片球菌。
6.根据权利要求1所述的茶粉组合物,其特征在于,所述功能糖包括功能性低聚糖和功能性膳食纤维;
所述功能性低聚糖包括水苏糖、棉籽糖、异麦芽酮糖、乳酮糖、低聚果糖、低聚木糖、低聚半乳糖、低聚异麦芽糖、低聚异麦芽酮糖、低聚龙胆糖、大豆低聚糖、低聚壳聚糖中的一种或几种;
所述功能性膳食纤维包括菊粉、天然抗性淀粉、果胶、藻胶、纤维素、魔芋多糖、瓜儿胶、甲壳素中的一种或几种。
7.根据权利要求1-6任一项所述的茶粉组合物,其特征在于,所述原料还包括辅料,所述辅料为奶粉、二氧化硅、食用香精、木糖醇、微晶纤维素、二氧化硅、植物硬脂酸中的任意一种或多种。
8.根据权利要求7所述的茶粉组合物,其特征在于,所述茶粉组合物为固态或液态,所述固态包括粉剂、颗粒剂。
9.权利要求1-8任一项所述的茶粉组合物的制备方法,其特征在于,将各原料混匀即可;
所述混匀优选采用混料机,混合10-15min即可。
10.权利要求1-8任一项所述的茶粉组合物在解酒护肝食品中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610437434.7A CN106035806A (zh) | 2016-06-17 | 2016-06-17 | 一种茶粉组合物及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610437434.7A CN106035806A (zh) | 2016-06-17 | 2016-06-17 | 一种茶粉组合物及其制备方法和应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN106035806A true CN106035806A (zh) | 2016-10-26 |
Family
ID=57167699
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610437434.7A Pending CN106035806A (zh) | 2016-06-17 | 2016-06-17 | 一种茶粉组合物及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106035806A (zh) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107006747A (zh) * | 2017-04-20 | 2017-08-04 | 南昌大学 | 一种醒酒护肝山楂发酵饮料的制备方法 |
CN108578589A (zh) * | 2018-03-13 | 2018-09-28 | 广西壮族自治区亚热带作物研究所 | 一种复合解酒泡腾片及其制备方法 |
CN108813581A (zh) * | 2018-05-18 | 2018-11-16 | 尚方堂中药有限公司 | 一种保肝解酒组合物及其制备方法 |
CN109275714A (zh) * | 2018-11-29 | 2019-01-29 | 扬州市扬大康源乳业有限公司 | 一种解酒护肝酸奶及其制备方法 |
CN110122878A (zh) * | 2019-06-14 | 2019-08-16 | 山东圣奥生物科技有限公司 | 一种含益生菌的解酒护肝组合物及制备方法及应用 |
CN111406856A (zh) * | 2020-03-11 | 2020-07-14 | 天津科技大学 | 一种解酒护肝功能性发酵饮料及其制备方法 |
CN113273659A (zh) * | 2021-06-03 | 2021-08-20 | 佛山市朗芯生物科技有限公司 | 一种含益生菌的解酒护肝功能性固体饮料及其制备方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101703234A (zh) * | 2009-11-05 | 2010-05-12 | 安吉依思味食品有限公司 | 一种益生菌组合物及其制备方法 |
CN103976090A (zh) * | 2014-06-04 | 2014-08-13 | 理想科技集团有限公司 | 一种通便消食茶珍及其制备方法 |
-
2016
- 2016-06-17 CN CN201610437434.7A patent/CN106035806A/zh active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101703234A (zh) * | 2009-11-05 | 2010-05-12 | 安吉依思味食品有限公司 | 一种益生菌组合物及其制备方法 |
CN103976090A (zh) * | 2014-06-04 | 2014-08-13 | 理想科技集团有限公司 | 一种通便消食茶珍及其制备方法 |
Non-Patent Citations (1)
Title |
---|
黄小勇等: "《中华国饮事典•茶苑•茶之养》", 31 August 2015, 武汉大学出版社 * |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107006747A (zh) * | 2017-04-20 | 2017-08-04 | 南昌大学 | 一种醒酒护肝山楂发酵饮料的制备方法 |
CN107006747B (zh) * | 2017-04-20 | 2020-04-24 | 南昌大学 | 一种醒酒护肝山楂发酵饮料的制备方法 |
CN108578589A (zh) * | 2018-03-13 | 2018-09-28 | 广西壮族自治区亚热带作物研究所 | 一种复合解酒泡腾片及其制备方法 |
CN108578589B (zh) * | 2018-03-13 | 2021-05-25 | 广西壮族自治区亚热带作物研究所 | 一种复合解酒泡腾片及其制备方法 |
CN108813581A (zh) * | 2018-05-18 | 2018-11-16 | 尚方堂中药有限公司 | 一种保肝解酒组合物及其制备方法 |
CN109275714A (zh) * | 2018-11-29 | 2019-01-29 | 扬州市扬大康源乳业有限公司 | 一种解酒护肝酸奶及其制备方法 |
CN110122878A (zh) * | 2019-06-14 | 2019-08-16 | 山东圣奥生物科技有限公司 | 一种含益生菌的解酒护肝组合物及制备方法及应用 |
CN111406856A (zh) * | 2020-03-11 | 2020-07-14 | 天津科技大学 | 一种解酒护肝功能性发酵饮料及其制备方法 |
CN111406856B (zh) * | 2020-03-11 | 2023-04-07 | 天津科技大学 | 一种解酒护肝功能性发酵饮料及其制备方法 |
CN113273659A (zh) * | 2021-06-03 | 2021-08-20 | 佛山市朗芯生物科技有限公司 | 一种含益生菌的解酒护肝功能性固体饮料及其制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106035806A (zh) | 一种茶粉组合物及其制备方法和应用 | |
CN105146614B (zh) | 一种功能性钙果酵素、酵素饮料及其生产方法 | |
CN104824548B (zh) | 枸杞复合保健酵素及其制备方法 | |
JP6737779B2 (ja) | 微生物製剤の製造方法およびこれにより製造された微生物製剤 | |
CN108208853B (zh) | 一种解酒护肝益生菌低聚肽复合制剂及制备方法 | |
CN106173773A (zh) | 一种酵素益生菌固体饮料及其制备方法 | |
CN107496850B (zh) | 一种调节肠道微生态制剂的配方及应用 | |
CN105995976A (zh) | 一种具有降脂减肥作用的综合酵素粉及其应用 | |
CN106070848A (zh) | 一种茶粉组合物及其制备方法和应用 | |
CN107981324A (zh) | 姜黄发酵食品及其制备方法 | |
CN106722206A (zh) | 一种缓解消化道不适症状和/或情绪压力的组合物及其产品 | |
CN106072657A (zh) | 益生菌组合物及其制备方法 | |
CN111972670A (zh) | 一种润肠通便的组合物、固体饮料及应用 | |
CN106420847A (zh) | 辅助保护胃黏膜和/或缓解胃胀的组合物及其微生态制剂 | |
CN105641209A (zh) | 具有提高免疫力功能的益生菌组合物及其制备方法与应用 | |
JP2016520305A (ja) | 消化管微生物叢中のラクノスピラ科細菌及び体重との関連性 | |
CN105942128A (zh) | 一种草本酵母益生菌固体饮料及其制备方法和应用 | |
Chaturvedi et al. | The potential of non-dairy synbiotic instant beverage powder: Review on a new generation of healthy ready-to-reconstitute drinks | |
JP2023544655A (ja) | 排便を促進する組成物及びその用途 | |
KR20110041050A (ko) | 발효차 추출물을 함유하는 혈액 순환 개선 및 수족 냉증 개선용 조성물 | |
Pop et al. | Prebiotics and dairy applications | |
CN102742653B (zh) | 一种健脑安神益生菌羊奶片及其制备方法 | |
CN104983022A (zh) | 一种动物双歧杆菌发酵果蔬粉及其制备方法与应用 | |
CN110269889A (zh) | 微生态制剂及其制备方法和应用 | |
KR20230037761A (ko) | 차전자피가 함유된 장기능 개선용 건강기능식품 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20161026 |